Moleculin Biotech Inc (MBRX) News

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in...

Form 8-K - Current report

Form 8-K - Current report

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update PR Newswire HOUSTON, Nov...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and...

Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Form 8-K - Current report

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available PR Newswire HOUSTON...

Form 8-K - Current report